This course has expired. View available courses.
Endocrinology
Intensifying Therapy: Primary Care Patient Case
Type 2 diabetes is a common condition managed in primary care. Although clinical practice guidelines recommend specific targets for blood pressure, LDL-C and A1C, primary care research has demonstrated only a small portion of patients with type 2 diabetes are meeting these targets. With the Diabetes Canada 2020 guideline update, clinicians are still encouraged to meet glycemic targets, but there is an increased focus on selecting antihyperglycemic agents that can improve outcomes in patients with diabetes. This module will focus on providing recommendations on the intensification of antihyperglycemic therapy beyond metformin in people with type 2 diabetes.
This program has received an unrestricted educational grant or in-kind support from Novo Nordisk A/S.
DURATION
30 min
PROFESSION
Physician, Student, Specialist
# OF CREDITS
0.5
ACCREDITATION
Mainpro+
EXPIRY DATE
2023-01-20
Type 2 diabetes is a common condition managed in primary care. Although clinical practice guidelines recommend specific targets for blood pressure, LDL-C and A1C, primary care research has demonstrated only a small portion of patients with type 2 diabetes are meeting these targets. With the Diabetes Canada 2020 guideline update, clinicians are still encouraged to meet glycemic targets, but there is an increased focus on selecting antihyperglycemic agents that can improve outcomes in patients with diabetes. This module will focus on providing recommendations on the intensification of antihyperglycemic therapy beyond metformin in people with type 2 diabetes.
This program has received an unrestricted educational grant or in-kind support from Novo Nordisk A/S.
Faculty
Peter Lin, MD, CCFP
Kim Connelly, MBBS PhD FSCMR FCCS
James Kim, MBBCh, PgDip
Maureen Clement, MD, CCFP
Learning objectives
Upon successful completion of this continuing education module, the participant will be better able to:
- Apply the Diabetes Canada 2020 guideline pharmacotherapy treatment algorithm for managing people with type 2 diabetes
- Discuss the selection of antihyperglycemic agents in patients with cardiovascular and chronic kidney disease
- Individualize antihyperglycemic therapy based on the preferences of the person with diabetes